When we think about the future of medicine, we think about companies like Iovance. Iovance Biotherapeutics, Inc. is pioneering a transformational approach to treating cancer by harnessing the ability of the human immune system to recognize and attack diverse cancer cells in each patient. Their lead, late-stage TIL product candidate, lifileucel for metastatic melanoma, has the potential to become the first approved one-time cell therapy for a solid tumor cancer.
At this year's ISPE Annual Meeting in Orlando FL, I had the chance to sit down and talk about some of the things that Iovance is doing with Sumit Verma, Senior Vice President Global Strategic Manufacturing. It was obvious to me that not only is Sumit very engaged on the "facility" level of what needs to happen to make a successful facility for our modern therapeutics, but he is passionate about the patients that Iovance is helping. This isn't just a job, its a mission.
The future of cell and gene therapy is a fascinating one, and what Sumit and his team at Iovance Biotherapeutics are doing will have monumental, life saving effects in the lives of so many where before there was little hope. Listen in our conversation!